Call for Speaker Proposals
第2届
Oncology Clinical Trials
-癌治疗药临床试验学会-
藉由改善临床试验，促进开发癌治疗药
2月21日～23日
由于癌分子生物学研究近几年获得惊人的成果，在癌治疗药开发的领域，产生以前没有的许多新标的。许多因应这样标的的药剂，已经进入临床阶段，如火如荼进行因应各种疗法的癌治疗药临床试验。癌治疗药临床试验成功的主因很多，最重要的是临床前数据的质能否达到导出可验证的假设之水准。此外，与生物统计学、科学、组织、法规、伦理、经济等有关的主因，在医药品临床开发时具有重要的意义。
Who should attend: Scientists, biostatisticians, project managers, research investigators and other specialists involved in oncology clinical trials
Topics will include, but are not limited to:
- Translational clinical trials in oncology
- Evaluating pre-clinical evidence to avoid clinical development failures
- Molecular imaging in cancer clinical trials
- Prescreening patients for somatic mutations before randomization
- Biomarker-driven clinical trials
- Companion diagnostics in oncology clinical trials
- Advanced methodology for dose-finding clinical trials
- Dose finding for 乬nontoxic乭 drug
- Pharmacodynamic biomarkers and their use in clinical trials
- Role of randomization in middle development
- How to use surrogate outcomes in the light of lack of biomarker validation
- Regulatory and legal challenges and solutions
- Safety issues in cancer clinical trials
- Ways to increase patient enrollment
- Ethical issues related to biomarker use for patient selection (what is the threshold?)
- Cost effectiveness of clinical trials in the US and abroad
- Joint development: Industry-academic collaboration (identification (who takes responsibility), shared intellectual property, etc.)
The deadline for submission is July 29, 2011.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are
offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
